In this episode, we explore a major cancer research breakthrough, revealing how treatment-resistant pancreatic and lung cancers survive therapy by changing their cellular identity.

You’ll learn:

• What treatment-resistant cancer is and why pancreatic and lung cancers are so difficult to treat
•  How cancer cells “shapeshift” through a process called lineage plasticity to escape therapy
•  Why the KLF5 transcription factor plays a critical role in pancreatic cancer survival
•  How targeting enzymes RUVBL1 and RUVBL2 can weaken tumor-driving gene programs
•  What scientists discovered about the POU2F3–OCA-T1 molecular complex in aggressive lung cancers
•  Why targeting cellular identity rather than DNA mutations could redefine future cancer treatments
•  How these findings may improve combination therapies and guide future clinical trials

Researchers at Cold Spring Harbor Laboratory uncovered the molecular switches that allow certain tumors to change identity and resist treatment. By targeting the regulatory machinery behind these shifts, scientists may be able to stop cancer cells from adapting and continuing to grow.

Although these discoveries are still in the preclinical stage, they represent a promising new direction in oncology. Instead of chasing individual mutations, researchers are focusing on the systems that control which genes are active inside cancer cells.

If successful in future clinical trials, these strategies could help weaken treatment resistance and improve outcomes for patients facing aggressive pancreatic and lung cancers.

Blog Link: Researchers Crack Treatment-Resistant Pancreatic and Lung Cancers

Send us Fan Mail

Thank you for listening to The Onco Life Podcast, your trusted source for expert cancer information and patient-centered education.

Author: Dr. CHRISTINA NG VAN TZE

📍 Visit us at oncolifecentre.com
📞 Call: +603-2242-2620
📧 Book a consultation or ask a question — we're here to support your journey.